Tofacitinib


CAS No. : 477600-75-2

(Synonyms: Tasocitinib; CP-690550)

477600-75-2
Price and Availability of CAS No. : 477600-75-2
Size Price Stock
5mg $38 In-stock
10mg $60 In-stock
25mg $80 In-stock
50mg $96 In-stock
100mg $132 In-stock
200mg $180 In-stock
250mg $220 In-stock
500mg $336 In-stock
1g $500 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-40354
M.Wt: 312.37
Formula: C16H20N6O
Purity: >98 %
Solubility: Ethanol : 2.5 mg/mL (ultrasonic);DMSO : ≥ 116.67 mg/mL
Introduction of 477600-75-2 :

Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury[1][2][3][4][5][6][7][8][9]. In Vitro:Tofacitinib (1000 nM; 3 days) (Tasocitinib) suppresses proliferation and Th17 cell differentiation of SKG mouse spleen CD4+ T cells in vitro[2].
Tofacitinib (5 days) suppresses differentiation of naïve SKG mouse lung-infiltrating cells into CD11b+ Gr1dim and CD11b+ CD11c+ cells, while increasing CD11bdim CD11c+ cell proportions in vitro[2].
Tofacitinib (5 days) facilitates expansion of MDSCs and suppresses BMDC differentiation from naïve SKG mouse bone marrow cells in vitro[2].
Tofacitinib (1 μM; 60 min) abrogates IL6-induced STAT3 phosphorylation and reduces fibrotic marker expression in neonatal foreskin primary fibroblasts[4].
Tofacitinib (2 μM; 24 h) alters gene expression in white adipocytes, generating a distinct Tofacitinib gene signature[4].
Tofacitinib (1 μM; 24 hr pre-incubation) inhibits IL-4-induced JAK/STAT6 signaling in primary murine bone marrow macrophages, but does not provide sustained inhibitory activity after a 72 hr washout period[5].
Tofacitinib selectively inhibits Janus kinases 1, Janus kinases 2, and Janus kinases 3 with functional specificity for Janus kinases 1 and Janus kinases 3 over Janus kinase 2, and suppresses cytokine-mediated immune cell activation and pro-inflammatory signaling in vitro[7]. In Vivo:Tofacitinib (10-75 mg/kg; i.g.; daily; 1 week) (Tasocitinib) alleviates LPS-induced depressive-like behaviors and associated hippocampal pathological changes, with 30 mg/kg showing robust efficacy in reducing microgliosis, normalizing cytokine levels, and restoring BDNF levels[1].
Tofacitinib (30 mg/kg; i.g.; daily; 13 days) effectively improves depressive-like behaviors, including social avoidance, in CSDS-induced mice[1].
Tofacitinib (10-75 mg/kg; i.g.; daily; 1 week) is well-tolerated and does not affect emotional status in normal mice[1].
Tofacitinib (30 mg/kg; i.p.; twice daily; 5 days/week; 5 weeks) reduces established skin fibrosis in male TSK1/+ mice on a C57BL/6 background[4].
Tofacitinib (20 mg/kg; i.p.; three times per week; 8 weeks) ameliorates zymosan-induced interstitial lung disease in male SKG mice by increasing lung MDSCs to 72.8% of total lung cells and reducing pathogenic Th17 cells, ILC1s, and GM-CSF+ ILCs[2].
Tofacitinib (1-10 mg/kg; i.g.; every 6 hours starting 2 hours post-CLP) improves the 7-day survival rate of CLP-induced septic rats to 70%, reduces acute lung injury, and inhibits the JAK-STAT/NF-κB pathway[3].
Tofacitinib (10 mg/kg; p.o.; daily; 8 weeks) prevents murine lupus manifestations, modulates innate and adaptive immune responses, improves vascular function, and restores lipoprotein homeostasis in lupus-prone MRL/lpr mice[8].
Tofacitinib (10 mg/kg; p.o.; daily; 6 weeks) ameliorates established murine lupus manifestations and modulates interferon responses in lupus-prone MRL/lpr mice[8].
Tofacitinib (10 mg/kg/day; i.g.; every 2 days; 2 weeks) relieves liver fibrosis in a mouse model of chronic autoimmune hepatitis[9].

Your information is safe with us.